vs
Adaptive Biotechnologies Corp（ADPT）与BioNTech SE（BNTX）财务数据对比。点击上方公司名可切换其他公司
BioNTech SE的季度营收约是Adaptive Biotechnologies Corp的21.2倍（$1.5B vs $71.7M）。BioNTech SE净利率更高（-1.9% vs -18.9%，领先17.1%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
ADPT vs BNTX — 直观对比
营收规模更大
BNTX
是对方的21.2倍
$71.7M
净利率更高
BNTX
高出17.1%
-18.9%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $1.5B |
| 净利润 | $-13.6M | $-28.7M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | -3.1% |
| 净利率 | -18.9% | -1.9% |
| 营收同比 | 51.0% | — |
| 净利润同比 | 59.7% | — |
| 每股收益（稀释后） | $-0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTBNTX
| Q4 25 | $71.7M | — | ||
| Q3 25 | $94.0M | $1.5B | ||
| Q2 25 | $58.9M | $260.8M | ||
| Q1 25 | $52.4M | $182.8M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.4M | $1.2B | ||
| Q2 24 | $43.2M | $128.7M | ||
| Q1 24 | $41.9M | $187.6M |
净利润ADPTBNTX
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | $-28.7M | ||
| Q2 25 | $-25.6M | $-386.6M | ||
| Q1 25 | $-29.9M | $-415.8M | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | $198.1M | ||
| Q2 24 | $-46.2M | — | ||
| Q1 24 | $-47.5M | — |
毛利率ADPTBNTX
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTBNTX
| Q4 25 | -17.8% | — | ||
| Q3 25 | 10.9% | -3.1% | ||
| Q2 25 | -42.5% | -192.1% | ||
| Q1 25 | -56.4% | -292.2% | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | 0.8% | ||
| Q2 24 | -109.6% | -750.7% | ||
| Q1 24 | -116.5% | -270.4% |
净利率ADPTBNTX
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | -1.9% | ||
| Q2 25 | -43.5% | -148.2% | ||
| Q1 25 | -56.9% | -227.5% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | 15.9% | ||
| Q2 24 | -107.0% | — | ||
| Q1 24 | -113.5% | — |
每股收益（稀释后）ADPTBNTX
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — | ||
| Q1 24 | $-0.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | — |
| 总资产 | $512.7M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTBNTX
| Q4 25 | $70.5M | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | $43.2M | — | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $38.1M | — | ||
| Q2 24 | $59.8M | — | ||
| Q1 24 | $71.2M | — |
股东权益ADPTBNTX
| Q4 25 | $218.8M | — | ||
| Q3 25 | $204.4M | — | ||
| Q2 25 | $179.7M | — | ||
| Q1 25 | $190.4M | — | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | — | ||
| Q1 24 | $274.9M | — |
总资产ADPTBNTX
| Q4 25 | $512.7M | — | ||
| Q3 25 | $490.6M | — | ||
| Q2 25 | $496.6M | — | ||
| Q1 25 | $510.9M | — | ||
| Q4 24 | $539.4M | — | ||
| Q3 24 | $558.5M | — | ||
| Q2 24 | $584.9M | — | ||
| Q1 24 | $620.3M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | — |
| 自由现金流经营现金流 - 资本支出 | $1.4M | — |
| 自由现金流率自由现金流/营收 | 2.0% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | — |
8季度趋势，按日历期对齐
经营现金流ADPTBNTX
| Q4 25 | $2.1M | — | ||
| Q3 25 | $-7.1M | — | ||
| Q2 25 | $-12.4M | — | ||
| Q1 25 | $-28.5M | — | ||
| Q4 24 | $-12.5M | — | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $-17.3M | — | ||
| Q1 24 | $-38.4M | — |
自由现金流ADPTBNTX
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
自由现金流率ADPTBNTX
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
资本支出强度ADPTBNTX
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
现金转化率ADPTBNTX
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
BNTX
暂无分部数据
